Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.

AKTUALNOŚCI >> Mabion initiated the national and regional PCT phases of the patent application for the use of MabionCD20 in the treatment of Multiple Sclerosis (MS) patients

Mabion initiated the national and regional PCT phases of the patent application for the use of MabionCD20 in the treatment of Multiple Sclerosis (MS) patients

Mabion submitted an international patent application to selected patent offices, which triggered a national and regional phase to obtain patent protection in nearly 50 countries for its drug candidate, MabionCD20 (rituximab) - developed for a number of clinical uses, including multiple sclerosis therapy. As an innovative therapy for the treatment of multiple sclerosis patients, it is intended to combine MabionCD20 with other active substances (the “MabionMS project”). To date, rituximab has not yet been registered for the treatment of multiple sclerosis.

More information

© Mabion S.A. all rights reserved Polityka Prywatności